As Trump’s trade war led stocks to post their worst first quarter since 2022, diversification proved its worth.
Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback